Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2009 7
2010 5
2011 5
2012 14
2013 16
2014 11
2015 5
2016 9
2017 10
2018 11
2019 12
2020 7
2021 5
2022 6
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 31432367

101 results

Results by year

Filters applied: . Clear all
Page 1
Agreement between molecular subtyping and surrogate subtype classification: a contemporary population-based study of ER-positive/HER2-negative primary breast cancer.
Lundgren C, Bendahl PO, Borg Å, Ehinger A, Hegardt C, Larsson C, Loman N, Malmberg M, Olofsson H, Saal LH, Sjöblom T, Lindman H, Klintman M, Häkkinen J, Vallon-Christersson J, Fernö M, Rydén L, Ekholm M. Lundgren C, et al. Breast Cancer Res Treat. 2019 Nov;178(2):459-467. doi: 10.1007/s10549-019-05378-7. Epub 2019 Aug 20. Breast Cancer Res Treat. 2019. PMID: 31432367 Free PMC article.
Molecular subtyping of male breast cancer by immunohistochemistry.
Kornegoor R, Verschuur-Maes AH, Buerger H, Hogenes MC, de Bruin PC, Oudejans JJ, van der Groep P, Hinrichs B, van Diest PJ. Kornegoor R, et al. Mod Pathol. 2012 Mar;25(3):398-404. doi: 10.1038/modpathol.2011.174. Epub 2011 Nov 4. Mod Pathol. 2012. PMID: 22056953 Free article.
PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.
Bastien RR, Rodríguez-Lescure Á, Ebbert MT, Prat A, Munárriz B, Rowe L, Miller P, Ruiz-Borrego M, Anderson D, Lyons B, Álvarez I, Dowell T, Wall D, Seguí MÁ, Barley L, Boucher KM, Alba E, Pappas L, Davis CA, Aranda I, Fauron C, Stijleman IJ, Palacios J, Antón A, Carrasco E, Caballero R, Ellis MJ, Nielsen TO, Perou CM, Astill M, Bernard PS, Martín M. Bastien RR, et al. BMC Med Genomics. 2012 Oct 4;5:44. doi: 10.1186/1755-8794-5-44. BMC Med Genomics. 2012. PMID: 23035882 Free PMC article.
Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial.
Viale G, de Snoo FA, Slaets L, Bogaerts J, van 't Veer L, Rutgers EJ, Piccart-Gebhart MJ, Stork-Sloots L, Glas A, Russo L, Dell'Orto P, Tryfonidis K, Litière S, Cardoso F; MINDACT investigators. Viale G, et al. Breast Cancer Res Treat. 2018 Jan;167(1):123-131. doi: 10.1007/s10549-017-4509-9. Epub 2017 Sep 19. Breast Cancer Res Treat. 2018. PMID: 28929359 Clinical Trial.
Frequency of breast cancer subtypes among African American women in the AMBER consortium.
Allott EH, Geradts J, Cohen SM, Khoury T, Zirpoli GR, Bshara W, Davis W, Omilian A, Nair P, Ondracek RP, Cheng TD, Miller CR, Hwang H, Thorne LB, O'Connor S, Bethea TN, Bell ME, Hu Z, Li Y, Kirk EL, Sun X, Ruiz-Narvaez EA, Perou CM, Palmer JR, Olshan AF, Ambrosone CB, Troester MA. Allott EH, et al. Breast Cancer Res. 2018 Feb 6;20(1):12. doi: 10.1186/s13058-018-0939-5. Breast Cancer Res. 2018. PMID: 29409530 Free PMC article.
101 results